Articles

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice

Ivone U S Leong, Claudia P Cabrera, Valentina Cipriani, et al.J Clin Oncol. 2025 Feb 20;43(6):682-693

As part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as part of a genomic medicine service. We identified clinically relevant PGx v... Read More

24 Mar, 2026

Germline Testing in Patients with Breast Cancer: ASCO–Society of Surgical Oncology Guideline

Isabelle Bedrosian, Mark R. Somerfield, Maria Isabel Achatz, et al. J. Clin Oncol 2024 Feb 10;42(5):584-604

An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. Forty-seven articles met eligibility criteria for the germline mutation testing recommendations: 18 for the genetic counseling recommendations. BRCA1/2 mutation testing should ... Read More

24 Mar, 2026

The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer

Alexandre Bolze, Elizabeth T. Cirulli, Catherine Hajek,. JAMA Oncol. 2024;10(2):236-239

Genetic information is not being used to identify women at lower risk of breast cancer or other diseases in clinical practice. With the new US Preventive Services Task Force guidelines lowering the age for mammogram screening for all, there is a potential benefit in identifying women at lower risk of disease who may de... Read More

24 Mar, 2026

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention

The current method of BRCA testing for breast and ovarian cancer prevention, which is based on family history, often fails to identify many carriers of pathogenic variants. Population-based genetic testing offers a transformative approach in cancer prevention by allowing for proactive identification of any high-risk in... Read More

24 Mar, 2026

Genomic Screening at a Single Health System

Juliann M Savatt 1, Melissa A Kelly 1, Amy C Sturm 1 2, Cara Z McCormick . JAMA Netw Open. 2025 Mar 3;8(3):e250917

Completion of the Human Genome Project prompted predictions that genomics would transform medicine, including through genomic screening that identifies potentially medically actionable findings that could prevent disease, detect it earlier, or treat it better. However, genomic screening remains anchored in research and... Read More

24 Mar, 2026

Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare system

Isabelle A. Lucas Beckett, Kate R. Emery, Josiah T. Wagner. npj Genomic Medicine | (2025) 10:50

Genomic medicine is now at a point where increased sequencing speed, cost reduction, and scalable cloud platforms can enable population-scale clinical sequencing. As 88% of US hospitals are community hospitals, integrating genomics into community healthcare represents a significant opportunity for greater genomic acces... Read More

24 Mar, 2026

Identification of Patients at Elevated Cancer Risk through a community‑based genetic testing program

Danielle Brabender, Emily Siegel, Julie O. Culver, et al. Ann Surg Oncol (2025) 32:9041–9049

Only a subset of individuals meeting National Comprehensive Cancer Network (NCCN) guidelines for genetic screening of hereditary cancers are being offered testing. A total of 14,192 women were screened, with 3224 (23%) meeting NCCN criteria. Of these patients, 50.3% opted for testing and 7.6% were found to have P/LP v... Read More

24 Mar, 2026

Germline Genetic Testing After Cancer Diagnosis

Allison W Kurian, Paul Abrahamse, Allison Furgal, et al. JAMA. 2023 Jul 3;330(1):43-51

Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. Among 1 369 602 patients diagnosed with cancer between 2013 and 2019 in California and Geor... Read More

24 Mar, 2026

The financial toxicity of cancer: unveiling global burden and risk factors – a systematic review and meta-­ analysis

Tegene Kitaw. Befkad Tilahun, Alemu Zemariam, et al. BMJ Glob Health 2025;10:e017133.

Cancer, a major global health challenge, not only threatens lives but also imposes severe financial burdens, known as ‘financial toxicity’. This strain extends beyond treatment costs to include indirect expenses like lost income and out-­ of-­ pocket payments. Despite its urgency, global insights remain fragmented, oft... Read More

24 Mar, 2026

Working, Low Income, and Cancer Caregiving: Financial and Mental Health Impacts

Cathy J Bradley, Sara Kitchen, Kelsey M Owsley . J Clin Oncol. 2023 Jun 1;41(16):2939-2948

Approximately 6 million people provide caregiving to people diagnosed with cancer. Many must remain employed to support their household and to have access to health insurance. It is unknown if caregiving for a spouse diagnosed with cancer is associated with greater financial and mental stress relative to providing care... Read More

24 Mar, 2026